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ABSTRACT 
 
Purpose:  The endoplasmic reticulum-associated degradation (ERAD) pathway is 
responsible for the translocation of misfolded proteins across the ER membrane into the 
cytosol for subsequent degradation by the proteasome. In order to understand the 
spectrum of clinical and molecular findings in a complex neurological syndrome, we 
studied a series of eight patients with inherited deficiency of N-glycanase 1 (NGLY1), a 
novel disorder of cytosolic ERAD dysfunction. 
Methods:  Whole-genome, whole-exome or standard Sanger sequencing techniques 
were employed. Retrospective chart reviews were performed in order to obtain clinical 
data. 
Results: All patients had global developmental delay, a movement disorder, and 
hypotonia. Other common findings included hypo- or alacrima (7/8), elevated liver 
transaminases (6/7), microcephaly (6/8), diminished reflexes (6/8), hepatocyte 
cytoplasmic storage material or vacuolization (5/6), and seizures (4/8). The nonsense 
mutation c.1201A>T (p.R401X) was the most common deleterious allele.  
Conclusions: NGLY1 deficiency is a novel autosomal recessive disorder of the ERAD 
pathway associated with neurological dysfunction, abnormal tear production, and liver 
disease. The majority of patients detected to date carry a specific nonsense mutation 
that appears to be associated with severe disease. The phenotypic spectrum is likely to 
enlarge as cases with a more broad range of mutations are detected.  
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INTRODUCTION 
 The enzyme N-glycanase 1 (NGLY1), also known as peptide:N-glycanase 
(PNGase, EC 3.5.1.52), catalyzes protein deglycosylation by cleaving the -aspartyl 
glycosylamine bond of N-linked glycoproteins with the subsequent release of intact N-
glycan species [1]. NGLY1 activity was first described in almond seeds [1], but is 
ubiquitously present across a wide range of species, including bacteria [2], yeast [3-5], 
amoeba [6],  fish [7], and mammals [8,9]. Evidence suggests that NGLY1 participates 
as a key cytoplasmic component of the endoplasmic reticulum-associated degradation 
(ERAD) machinery along with the AAA ATPase complex p97 [10,11]. The ERAD 
pathway is a mechanism for identifying and degrading misfolded glycoproteins. N-
glycans that are high in mannose content act as quality control tags for proteins in the 
early stages of the secretory pathway [12,13]. Misfolded glycoproteins are detected by 
ER luminal lectins and are then translocated to the cytosol via the ERAD machinery, to 
be subsequently degraded by cytosolic enzymes including NGLY1 [14]. 
 
To date, a single patient with NGLY1 deficiency has been reported as part of a 
whole-exome sequencing (WES) study focusing on the utility of this technology to 
detect the underlying genetic etiology of disorders affecting patients with previously 
undiagnosed or unresolved genetic conditions [15]. Need et al. described a 3-year-old 
boy with compound heterozygous inactivating mutations in NGLY1 and suggested that 
this could be a new disorder. The initial patient had a clinical phenotype suggestive of a 
congenital disorder of glycosylation, although repeated transferrin isoelectric focusing 
and N-glycan analyses were normal. Liver biopsy showed accumulation of an 
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amorphous unidentified substance throughout the cytoplasm, a finding likely consistent 
with NGLY1 dysfunction, which would be expected to result in abnormal accumulation 
of misfolded glycoproteins because of impaired cytosolic degradation [15]. We now 
report clinical and molecular findings present in seven newly diagnosed patients with 
mutations in NGLY1, and further details related to the original case. These observations 
confirm NGLY1 deficiency as an inherited disorder associated with the ERAD process 
and document its clinical presentation. 
 
MATERIALS AND METHODS 
The Stanford Institutional Review Board approved this study. Clinical data were 
abstracted from the medical records by retrospective chart review. Further data were 
collected by direct interaction with the families of participating subjects.  
 
Exome sequencing was performed in Patient 1 (Duke University), Patients 5 and 
6 (University of British Columbia) and parents using the Illumina HiSeq2000 platform 
and the Agilent SureSelect Human All Exon 50 Mb Kit. For Patient 3 (Stanford 
University), the patient and parents were sequenced using both Illumina HiSeq2000 and 
Complete Genomics platforms.  Variants in Illumina-sequenced reads were called using 
both the Hugeseq and Real Time Genomics pipelines and Complete Genomics variants 
were identified by their own variant callers. For Patient 3 (Baylor College of Medicine) 
DNA was capture-sequenced using a commercially developed capture reagent 
(VCRome2).  Sequence data were generated on an Illumina HiSeq2000 producing an 
average coverage of 80x with >90% of targeted bases at 20x coverage or higher. WES 
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was performed on a clinical basis in three patients (Patient 2 [Baylor College of 
Medicine Whole Genome Laboratory, Houston, Texas], and Patients 6 and 7 [Emory 
Genetics Laboratory, Atlanta, Georgia]). Sanger sequencing of NGLY1 was performed 
in Patient 4 at Duke University and results were confirmed by a clinical laboratory 
(GeneDx, Gaithersburg, Maryland).   
 
RESULTS 
Case reports 
The clinical and molecular findings demonstrate clear clinical similarities of 
patients with NYGL1 deficiency, although some variation in overall severity was 
observed, with the most common mutation being associated with more severe 
outcomes (Table1 and Figure 1). All patients had global developmental delay, a 
movement disorder, and hypotonia. Other common findings included hypo- or alacrima 
(7/8), abnormal brain imaging (7/8), EEG abnormalities (7/8), elevated liver 
transaminases (6/7), microcephaly (6/8), diminished reflexes (6/8), hepatocyte 
cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve 
conduction (3/3). Two of the patients died prematurely at 9 months and 5 years of age. 
Pedigrees for all patients are shown in Figure 2. Short clinical summaries are provided 
below. Further details may be found in Supplementary Materials and Methods.  
 
Patient 1, a now 5-year-old male, presented in the neonatal period with 
involuntary movements, including athetosis involving the trunk and extremities and 
constant lip smacking and pursing while awake. Pregnancy and birth history were 
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unremarkable. He had mild neonatal jaundice requiring phototherapy, but otherwise 
appeared well. Global developmental delay, hypotonia, intractable multifocal epilepsy, 
consisting of myoclonic seizures, drop attacks, and staring or tonic episodes, and liver 
disease were present in infancy. He has cortical vision loss and congenital alacrima and 
corneal ulcerations with scarring were noted at age 4 years. Now, at age 5 years, the 
movement disorder has not abated and he has central hypotonia and global 
developmental delay.  
 
Patient 2, a now 20-year-old female, was born at 39 weeks of gestation via 
Cesarean section because of intrauterine growth retardation and an abnormal 
appearing placenta. At four months of age, hypotonia, developmental delay and 
elevated liver transaminases were noted. At approximately 4 years of age, a slight 
intention tremor and frequent involuntary movements of her neck, hands and arm were 
observed. At 5 years of age, she was noted to have ocular apraxia, distal tapering of 
hands and feet, and diminished deep tendon reflexes. She has cortical vision 
impairment, as well as alacrima and dry eyes that require lubrication, but has not 
developed corneal scarring. Presently, she has marked intellectual disabilities and 
requires total care. She has very little expressive speech and communicates through an 
electronic speech-generating device. She continues to ambulate with a walker.   
 
Patient 3, a now 4-year-old girl, was born via Cesarean section at term for a non-
reassuring fetal heart tracing and was monitored in the NICU because of poor feeding 
and lethargy. The pregnancy was complicated by a positive second trimester screen 
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noting increased risk for Smith-Lemli Opitz syndrome (SLOS) and trisomy 18 (AFP 1.63 
MoM, uE3 0.26 MoM, hCG 0.54 MoM, inhibin 1.02 MoM), but karyotype on 
amniocentesis was normal. As a neonate, she had hyperbilirubinemia that was treated 
with phototherapy and was noted to have elevated liver transaminases and transient 
thrombocytopenia.  
 
In infancy, she was noted to have global developmental delay, acquired 
microcephaly, bilateral exotropia, hypotonia, constipation, and intermittent mild lactic 
acidemia (3.7 to 7.5 mM, normal <3). At approximately age 1 year, the parents noticed 
that she did not make tears when crying, although she had adequate tear production to 
keep her eyes moist. She has had intermittent chalazions, but no corneal scarring. She 
also developed staring spells, lasting up to 15 seconds, at approximately age 1 year; 
these episodes occur about once daily and can be interrupted by gentle contact. By age 
17 months she had developed an extrapyramidal movement disorder consisting of 
asynchronous myoclonic jerks of the limbs and shoulders and subtle choreoathetotic 
movements of the hands and fingers. At 4 years she can ambulate unassisted, although 
her gait is unsteady, and communicates with vocalizations, gestures and use of a 
speech-generating device.  
 
Patient 4, a now 2-year-old boy, was delivered by Cesarean section at 38 weeks 
of gestation after fetal distress was noted on cardiotocography.  Pregnancy history was 
positive for intrauterine growth restriction (IUGR) and oligohydramnios. He had mild 
hyperbilirubinemia, but otherwise his neonatal course was unremarkable and he was 
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discharged on day of life three. Intermittent head flexion was noted at 6 months, and an 
EEG at 8 months showed generalized poly-spike discharges. Soon thereafter, mild tonic 
seizures with head and body flexion started, and evolved to single, symmetric spasms 
with bilateral arm extension. Involuntary movements of the upper extremities were also 
noted at this time. In addition, global developmental delay, bilateral ptosis, abnormal 
tear production, elevated liver transaminases (3 to 4 times upper limit of normal), and 
constipation were noted in infancy. He has had recurrent episodes of 
keratoconjunctivitis and poor lid closure during sleep with resultant corneal scarring. 
 
Patient 5, a boy who died at the age of 5 years, was born at term following a 
pregnancy that was complicated by a positive second trimester serum screening for 
trisomy 18 and Smith-Lemli-Opitz syndrome (SLOS) (AFP 1.97 MoM, uE3 0.24 MoM 
and hCG 0.48 MoM). Cytogenetic analysis of cultured amniocytes showed a normal 
male karyotype and measurement of 7-dehydrocholesterol in amniotic fluid excluded 
SLOS. Because of concerns for IUGR and a non-reassuring stress test, he was 
delivered by Cesarean section at 36 weeks of gestation. He was noted to have mild 
flexion contractures of both knees, but had an uneventful neonatal period.  He had 
global developmental delay and constant movements of his arms and legs since early 
infancy and developed head bobbing at 7 months. At 8 months, liver transaminase 
elevations (approximately 1.5 times the upper limit of normal) were noted, and the 
elevations persisted until age 3 ½ years. Although his reflexes appeared normal in 
infancy, they were diminished by age 2 years and at 38 months could no longer be 
elicited. During the second year of life, he was noted to have dry eyes that were treated 
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with lubricant drops at bedtime, and microcephaly was present by 16 months. At 2 ½ 
years, he developed myoclonic seizures that became intractable despite numerous 
therapeutic trials. Between the ages of 10 months and five years, he showed slow 
developmental progress, but regressed during the last year. He died at age 5 years 
following a viral illness and a prolonged seizure.  
 
Patient 6 is the younger sister of Subject 5.  The pregnancy was also 
complicated by a positive second trimester serum screen for trisomy 18 and SLOS (AFP 
0.87 MoM, uE3 0.31 MoM, hCG 0.57 MoM). Cytogenetic analysis of cultured 
amniocytes showed a normal female karyotype. She was delivered by Cesarean section 
at 35 weeks of gestation following an ultrasound that was concerning for IUGR. She had 
jaundice requiring phototherapy, but her course in the nursery was otherwise 
uneventful. By age 9 months, developmental delay was apparent and she had 
developed hypotonia, microcephaly, a mildly myopathic-appearing face and constant 
involuntary movements with a tendency to hyperextend her arms and close her fists. At 
9 ½ months of age, she died unexpectedly in her sleep and the cause of death remains 
unknown.  
 
Patient 7, a now 3-year-old girl, was born at term via scheduled Cesarean 
section and, other than mild jaundice, did not have any neonatal complications. Prenatal 
screen showed an increased risk for trisomy 21. In infancy, she was noted to have 
strabismus, hypotonia, athetoid arm and hand movements, clasped hands, and 
elevated liver transaminases (approximately 3 times upper limit of normal).  
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Microcephaly was present by age 2 years. In addition, severe developmental delay was 
present, but she has shown slow progress without regression. She learned to sit alone 
and started to crawl at 2 years, but had no words.  
 
Patient 8, a now 16-year-old girl, is the older sister of Subject 7. She was born at 
term via Cesarean section for decreased fetal movement and bradycardia. Prenatal 
history was significant for IUGR. She had cyanosis at birth and required resuscitation. 
Anal stenosis requiring dilatation was noted in the first week of life, but she did not have 
further neonatal problems and was discharged home on day of life 7. She was noted to 
have hypotonia, a movement disorder consisting of head bobbing and extremity 
athetosis, and developmental delay in early infancy. At 3 years, she could stand 
unsupported, ambulate with a walker, and started to babble. Seizures developed at age 
11 years and she lost all mobility. Other medical history includes acquired microcephaly, 
an inability to close her eyes completely during sleep, chronic conjunctivitis, corneal 
clouding, hypolacrima, strabismus, hearing impairment, gastro-esophageal reflux, 
chronic constipation, severe scoliosis and talipes equinovarus.  
 
Sequencing results 
The nonsense mutation c.1201A>T (p.R401X) was the most common deleterious 
allele identified, present in homozygous state in 5 of 8 cases and in compound 
heterozygous state in one case. Patients 2 and 3 did not carry the c.1201A>T 
(p.R401X) mutation and their clinical phenotype was relatively mild in comparison 
(Table 1). 
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For Patient 1, whole exome sequencing (WES) performed as part of a research 
protocol detected putative knock out mutations forming a compound heterozygote 
genotype in the NGLY1 gene (Maternal frameshift: Q631S. at cDNA level: C1891del in 
transcript ENST00000280700. EXON 12. Paternal nonsense: 3_25750426_A, which 
causes a nonsense mutation, R401X, in transcript ENST00000280700. At the cDNA 
level this is A1201T EXON 8) [15]. 
 
For Patient 2, WES (Baylor College of Medicine Whole Genome Laboratory) 
revealed a homozygous mutation in exon 9 of the NGLY1 gene denoted as c.1370dupG 
or p.R458fs. Both parents were confirmed to be heterozygous carriers by Sanger 
sequencing. The mutation causes a frame shift in codon 458, causing insertion of 13 
incorrect residues before a stop codon is introduced towards the end of exon 9. The 
mutation was not seen in any of 3321 other subjects sequenced at Duke, nor was it 
seen in 6503 subjects on the Exome Variant Server (NHLBI GO Exome Sequencing 
Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) [accessed June 
2013]). 
 
For Patient 3, WES and whole-genome sequencing were performed using 
research protocols at Baylor College of Medicine and Stanford University. Mutations in 
NGLY1 that followed a compound heterozygous inheritance pattern were identified by at 
least 2 of the variant calling approaches at each site (see Supplemental Materials and 
Methods).  A stop gain mutation caused by a G>A mutation at position 3:25761670 
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(hg19) resulting in p.R542X was identified in both the father and daughter. Secondly, a 
3 base pair in-frame deletion TCC> beginning at position 3:25775416 (hg19) was 
identified in both the mother and daughter. At additional G>T mutation resulting in a 
heterozygous SMP at position 3:25777564 was identified in the daughter, mother and 
father. This mutation was called by two programs in the daughter and one program in 
the mother and father. This mutation was not previously observed in 1000 genomes and 
is a coding region; however, it is present in heterozygous form in all three individuals.  
 
 For Patient 4, Sanger sequencing (Duke University) detected a homozygous 
nonsense mutation, p.R401X, at position 3:25775422 (hg19) in transcript 
ENST00000280700. At the cDNA level this is c.1201A>T in exon 8 of NGLY1. This 
finding was confirmed in a CLIA-certified laboratory (GeneDx). 
 
For Patients 5 and 6, the variant in NGLY1, single nucleotide variant T >A at 
position 3:25775422 (hg19), which was called to be homozygous in both children, was 
present in the mother’s exome as a heterozygous call (see Supplementary Materials 
and Methods). The NGLY1 variant was then independently validated by Sanger 
sequencing in both patients and both parents. This base pair substitution causes a 
nonsense mutation, R401X.  
 
 For Patients 7 and 8, WES (performed commercially at Emory University) 
detected a homozygous nonsense mutation, R401X, at position 3:25775422 (hg19) in 
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transcript ENST00000280700 in both siblings. At the cDNA level this is c.1201A>T in 
exon 8 of NGLY1. 
 
DISCUSSION 
 The finding of compound heterozygous knockout mutations in NGLY1 in the 
original case suggested that NGLY1 deficiency (OMIM 615273) represents a new 
disorder [15]. Soon after the initial report, we were able to identify the seven additional 
cases reported herein, therefore confirming NGLY1 deficiency as an inherited disorder 
of the ERAD pathway and the first to be identified that involves the cytosolic 
proteasome. The rapid ascertainment of cases occurred over a period of several 
months and was assisted by strong advocacy from families and connections made 
possible by the internet and social media (see Editorial Commentary). NGLY1-deficient 
patients have a striking clinical triad consisting of abnormal tear production, 
choreoathetosis and liver disease. In addition, global developmental delay, acquired 
microcephaly, hypotonia, EEG abnormalities with or without overt seizures, brain 
imaging abnormalities, a peripheral neuropathy, constipation and a history of IUGR 
were common findings. Some patients were noted to have dysmorphic features, but 
overall these were not considered to be particularly prominent (Table 1). Interestingly, 
low uE3 was present in three patients, including in two children who died and were 
found to have significant adrenal cortex vacuolation. Although adrenal function was not 
specifically evaluated in our patients, some degree of dysfunction remains possible. 
Further research will be required in order to determine if low uE3 might provide a clue to 
underlying NGLY1 deficiency. 
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 The constellation of features present in our cohort is in some ways reminiscent of 
the clinical features present in the congenital disorders of glycosylation (CDGs) [16]. 
CDGs feature multisystem disease involving particularly the central nervous system, 
heart, liver and gastrointestinal tract, and endocrine system. Indeed, the possibility of an 
underlying CDG was high in the differential diagnosis for all cases. Based on the initial 
report of a single NGLY1-deficient patient, a recent CDG review considered that NGLY1 
deficiency may even be considered to be the first “congenital disorder of 
deglycosylation” [17]. Although there are clearly similarities between NGLY1 deficiency 
and the CDGs as a whole, such as IUGR, failure to thrive, global developmental delay, 
and liver impairment, these features are non-specific and certain differences also are 
apparent. Unlike CDGs, NGLY1 deficiency does not appear to be associated with 
cerebellar atrophy, lipodystrophy, or significant heart manifestations. Our patients 
commonly had abnormalities detected on brain imaging, but findings were typically mild 
and non-specific (Table 1). In addition, at this early point of delineation of the clinical 
phenotypic spectrum, the combination of hypo- or alacrima and a movement disorder 
consisting of tremulousness and varying degrees of choreoathetosis appear to be 
pathognomonic for NGLY1 deficiency, but are not particularly associated with CDGs. 
 
  Mitochondrial disorders are also associated with multi-system disease and 
prominent neuromuscular involvement and such disorders were also considered as 
diagnostic possibilities in many cases. Lactic acidemia was variably present, but tended 
to be mild; chronic elevations were not noted in any patient. Mitochondrial electron 
transport chain enzymology was also performed in skin fibroblasts and tissues (muscle 
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or liver) when samples were available and no abnormalities were identified. A moderate 
reduction in mitochondrial DNA content was identified in a liver sample from a Patient 3 
(see Supplemental Materials and Methods). Although NGLY1 deficiency clearly involves 
multiple systems, features more strongly associated with mitochondrial disease, such as 
basal ganglia involvement, retinitis pigmentosa, cardiomyopathy, liver failure, and renal 
tubular acidosis were absent [18]. Significant brain disease was noted on autopsy in two 
siblings (Patients 5 and 6) who were found to have pathological changes consistent with 
hypoxic-ischemic encephalopathy (HIE). HIE has been associated with secondary 
mitochondrial dysfunction, but is not a typical feature of inherited mitochondrial 
disorders [19]. Neuronal loss and gliosis may occur in both HIE and mitochondrial 
disorders, but spongiform degeneration is more typically seen in the latter and was not 
present in our cases [20]. In short, although mitochondrial disorders may be reasonably 
placed on the differential diagnosis, the findings in NGLY1 deficiency are not particularly 
suggestive of this category of disease. 
 
 Recently, disorders associated with components of the ERAD pathway involving 
the Golgi apparatus, ER lipid raft-associated protein 1/2 (erlin1/2) complex, and E3-
ubiquitin ligase, have been identified. These conditions serve as interesting 
comparisons to deficiency of the cytosolic NGLY1. Mutations in MAN1B1, the gene 
coding for -1,2-mannosidase, are associated with non-syndromic autosomal recessive 
intellectual disability and subtle dysmorphic features [21]. -1,2-Mannosidase is a type II 
transmembrane protein that is primarily localized to the Golgi apparatus, where it 
undergoes O-glycosylation and participates in glycoprotein quality control [22,23]. 
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Profound intellectual disability, developmental regression and multiple contractures are 
features associated with autosomal recessive mutations in ERLIN2. In this case, 
abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate 
receptors (IP3) and other substrates by compromising the structure of the erlin1/2 
complex [24,25]. Despite the severity of the intellectual disability and neuromuscular 
findings, the results of brain imaging, electromyography and muscle biopsy appeared 
normal in the initial erlin2-deficient patients [24]. Another family was found to have a 
homozygous null mutation in ERLIN2, with affected individuals presenting with a 
hereditary spastic paraplegia phenotype [26].  
 
IP3 receptors form calcium channels in ER membranes and play an important 
role in mammalian cell signaling. Ultimately, IP3 receptors undergo rapid degradation 
via the ubiquitin-proteasome pathway in response to cell stimulation. Evidence suggests 
that RNF170, an E3-ubiquitin ligase, mediates ubiquitination and processing of the IP3 
receptor via interaction involving the erlin1/2 complex [25,27]. Mutations in RNF170 
cause a late-onset autosomal dominant sensory ataxia characterized by distal sensory 
loss, diminished to absent reflexes, wide-based gait, and normal brain imaging [28-30]. 
Abnormal E3-ubiquitin ligase activity has also been postulated to play a role in the 
pathogenesis of an autosomal dominant form of Charcot-Marie-Tooth disease [31]. In 
short, different steps of the quality control system for targeting and degrading misfolded 
proteins have been implicated in a number of neurological conditions with varying 
severity and either autosomal recessive or dominant inheritance.  
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NGLY1 is a cytoplasmic enzyme that participates in the proteasomal degradation 
of aberrant glycoproteins that are synthesized in the ER and subsequently translocated 
to the cytoplasm [1,10,32,33]. By performing the initial cleavage of bulky N-glycan 
chains on misfolded glycoproteins, NGLY1 makes further proteolysis possible; 
glycoproteins thus trimmed can enter the cylinder of the 20S proteasome to be acted 
upon by proteases [32]. Therefore, NGLY1 deficiency would be expected to result in 
accumulation of intact glycoproteins in the cytoplasm. The accumulation of an 
amorphous substance in the liver of three patients, as well as the vacuolization 
consistent with storage in two others, is supportive of this role of NGLY1 and may help 
explain the liver disease noted in our patients. The undefined stored substance likely 
represents accumulation of misfolded glycoproteins in the cytoplasm that have been 
retrotranslocated from the ER but cannot undergo further processing. Transferrin 
isoelectric focusing or mass spectrometry studies in NGLY1-deficient patients have 
been normal or only subtly abnormal. This is not particularly surprising, because these 
methods detect the absence or structural alterations of N-glycan chains [34], which 
would not be expected to accumulate in NGLY1 deficiency.  
 
The presence of axonal loss and gliosis in the brains suggestive of HIE suggests 
that NGLY1 plays a role in maintaining central nervous system integrity. A study in 
Caenorhabditis elegans detected peripheral nervous system defects, including aberrant 
neuronal branching, in animals with loss-of-function mutations in png-1, the ortholog of 
NGLY1 [35]. Neuronal branching abnormalities possibly relate to the peripheral 
neuropathy that seems to be relatively common in NGLY1 deficiency, but further studies 
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are needed to determine the underlying pathogenesis of both central and peripheral 
nervous system abnormalities found in our patients. 
 
The nonsense mutation c.1201A>T (p.R401X) was the most commonly detected 
deleterious allele in NGLY1, present in homozygous state in five of eight cases 
(Patients 4 to 8) and in compound heterozygous state in one case (Patient 1). Clearly, 
homozygous mutations associated with p.R401X cause a severe phenotype. However, 
the range of outcomes is variable, with some patients having an early demise, and 
others living at least into their teenage years.  Patients 2 and 3 appear to have a 
relatively mild phenotype and are the only two individuals in the current cohort who do 
not carry the c.1201A>T (p.R401X) mutation. Aside from these broad considerations, 
more detailed genotype-phenotype correlations will be possible only with the detection 
of further patients. Consistent with the severe presentation of NGLY1 deficiency, 
NGLY1 is amongst the 20th percentile of genes in the human genome that are the most 
intolerant of functional genetic variation in the human population [36], and we may 
expect that less extreme mutations than those seen here may also be associated with 
disease. 
 
In summary, NGLY1 deficiency is characterized by a constellation of unique 
features that should enable clinical recognition of this condition. The more salient 
features are elevation of AFP and liver enzymes in infancy with relative normalization in 
early childhood, accumulation of a substance with staining properties similar to 
glycogen (presumably misfolded glycoproteins) in hepatocyte cytoplasm, absent tears 
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resulting in blepharitis and corneal ulceration, a movement disorder and peripheral 
neuropathy. However, the transient nature of the AFP and liver transaminase elevation 
may make older or more mildly affected individuals difficult to detect; therefore, affected 
older children and adults may remain undiagnosed. However, the widespread clinical 
availability of WES and whole genome sequencing will likely result in further cases 
being detected, including those with a more mild phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
ACKNOWLEDGMENTS 
  
The authors gratefully acknowledge the generosity of the parents of all patients in 
providing samples and clinical data for this study. The Bertrand Might Research Fund 
(HHF) provided support for the study of subjects 1 and 2. Michael and Ellen Michelson, 
Tom and Diane Might, and Bobbie and Mike Wilsey provided additional support for this 
research. Christian Schaaf is a recipient of a Clinical Scientist Development Award by 
the Doris Duke Charitable Foundation. His work is generously supported by the Joan 
and Stanford Alexander Family. The sequencing work for subjects 5 and 6 was carried 
out through a research project (FORGE Canada) funded by the Government of Canada 
through Genome Canada, the Canadian Institutes of Health Research (CIHR) and the 
Ontario Genomics Institute. The FORGE Canada Steering Committee includes Kym 
Boycott (University of Ottawa), Jan Friedman (University of British Columbia, Jacques 
Michaud (Université de Montréal), Francois Bernier (University of Calgary), Michael 
Brudno (University of Toronto), Bridget Fernandez (Memorial University) Bartha 
Knoppers (McGill University), Mark Samuels (Université de Montréal), and Steve 
Scherer (University of Toronto). 
 
 
 
 
 
 
 23 
REFERENCES 
1. Takahashi N (1977) Demonstration of a new amidase acting on glycopeptides. 
Biochem Biophys Res Commun 76: 1194-1201. 
2. Plummer TH, Jr., Elder JH, Alexander S, Phelan AW, Tarentino AL (1984) 
Demonstration of peptide:N-glycosidase F activity in endo-beta-N-
acetylglucosaminidase F preparations. J Biol Chem 259: 10700-10704. 
3. Suzuki T, Park H, Hollingsworth NM, Sternglanz R, Lennarz WJ (2000) PNG1, a 
yeast gene encoding a highly conserved peptide:N-glycanase. J Cell Biol 149: 
1039-1052. 
4. Xin F, Wang S, Song L, Liang Q, Qi Q (2008) Molecular identification and 
characterization of peptide: N-glycanase from Schizosaccharomyces pombe. 
Biochem Biophys Res Commun 368: 907-912. 
5. Masahara-Negishi Y, Hosomi A, Della Mea M, Serafini-Fracassini D, Suzuki T (2012) 
A plant peptide: N-glycanase orthologue facilitates glycoprotein ER-associated 
degradation in yeast. Biochim Biophys Acta 1820: 1457-1462. 
6. Gosain A, Lohia R, Shrivastava A, Saran S (2012) Identification and characterization 
of peptide: N-glycanase from Dictyostelium discoideum. BMC Biochem 13: 9. 
7. Seko A, Kitajima K, Inoue Y, Inoue S (1991) Peptide:N-glycosidase activity found in 
the early embryos of Oryzias latipes (Medaka fish). The first demonstration of the 
occurrence of peptide:N-glycosidase in animal cells and its implication for the 
presence of a de-N-glycosylation system in living organisms. J Biol Chem 266: 
22110-22114. 
 24 
8. Suzuki T, Seko A, Kitajima K, Inoue Y, Inoue S (1993) Identification of peptide:N-
glycanase activity in mammalian-derived cultured cells. Biochem Biophys Res 
Commun 194: 1124-1130. 
9. Suzuki T, Seko A, Kitajima K, Inoue Y, Inoue S (1994) Purification and enzymatic 
properties of peptide:N-glycanase from C3H mouse-derived L-929 fibroblast 
cells. Possible widespread occurrence of post-translational remodification of 
proteins by N-deglycosylation. J Biol Chem 269: 17611-17618. 
10. Park H, Suzuki T, Lennarz WJ (2001) Identification of proteins that interact with 
mammalian peptide:N-glycanase and implicate this hydrolase in the proteasome-
dependent pathway for protein degradation. Proc Natl Acad Sci U S A 98: 11163-
11168. 
11. Jarosch E, Taxis C, Volkwein C, Bordallo J, Finley D, et al. (2002) Protein 
dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48. 
Nat Cell Biol 4: 134-139. 
12. Kato K, Kamiya Y (2007) Structural views of glycoprotein-fate determination in cells. 
Glycobiology 17: 1031-1044. 
13. Kamiya Y, Satoh T, Kato K (2012) Molecular and structural basis for N-glycan-
dependent determination of glycoprotein fates in cells. Biochim Biophys Acta 
1820: 1327-1337. 
14. Kamiya Y, Uekusa Y, Sumiyoshi A, Sasakawa H, Hirao T, et al. (2012) NMR 
characterization of the interaction between the PUB domain of peptide:N-
glycanase and ubiquitin-like domain of HR23. FEBS Lett 586: 1141-1146. 
 25 
15. Need AC, Shashi V, Hitomi Y, Schoch K, Shianna KV, et al. (2012) Clinical 
application of exome sequencing in undiagnosed genetic conditions. J Med 
Genet 49: 353-361. 
16. Freeze HH, Eklund EA, Ng BG, Patterson MC (2012) Neurology of inherited 
glycosylation disorders. Lancet Neurol 11: 453-466. 
17. Freeze HH (2013) Understanding human glycosylation disorders: biochemistry 
leads the charge. J Biol Chem 288: 6936-6945. 
18. DiMauro S, Schon EA (2003) Mitochondrial respiratory-chain diseases. N Engl J 
Med 348: 2656-2668. 
19. Gire C, Girard N, Nicaise C, Einaudi MA, Montfort MF, et al. (2002) Clinical features 
and neuroradiological findings of mitochondrial pathology in six neonates. Childs 
Nerv Syst 18: 621-628. 
20. Brown GK, Squier MV (1996) Neuropathology and pathogenesis of mitochondrial 
diseases. J Inherit Metab Dis 19: 553-572. 
21. Rafiq MA, Kuss AW, Puettmann L, Noor A, Ramiah A, et al. (2011) Mutations in the 
alpha 1,2-mannosidase gene, MAN1B1, cause autosomal-recessive intellectual 
disability. Am J Hum Genet 89: 176-182. 
22. Pan S, Wang S, Utama B, Huang L, Blok N, et al. (2011) Golgi localization of 
ERManI defines spatial separation of the mammalian glycoprotein quality control 
system. Mol Biol Cell 22: 2810-2822. 
23. Pan S, Cheng X, Sifers RN (2013) Golgi-situated endoplasmic reticulum alpha-1, 2-
mannosidase contributes to the retrieval of ERAD substrates through a direct 
interaction with gamma-COP. Mol Biol Cell 24: 1111-1121. 
 26 
24. Yildirim Y, Orhan EK, Iseri SA, Serdaroglu-Oflazer P, Kara B, et al. (2011) A 
frameshift mutation of ERLIN2 in recessive intellectual disability, motor 
dysfunction and multiple joint contractures. Hum Mol Genet 20: 1886-1892. 
25. Pearce MM, Wormer DB, Wilkens S, Wojcikiewicz RJ (2009) An endoplasmic 
reticulum (ER) membrane complex composed of SPFH1 and SPFH2 mediates 
the ER-associated degradation of inositol 1,4,5-trisphosphate receptors. J Biol 
Chem 284: 10433-10445. 
26. Alazami AM, Adly N, Al Dhalaan H, Alkuraya FS (2011) A nullimorphic ERLIN2 
mutation defines a complicated hereditary spastic paraplegia locus (SPG18). 
Neurogenetics 12: 333-336. 
27. Lu JP, Wang Y, Sliter DA, Pearce MM, Wojcikiewicz RJ (2011) RNF170 protein, an 
endoplasmic reticulum membrane ubiquitin ligase, mediates inositol 1,4,5-
trisphosphate receptor ubiquitination and degradation. J Biol Chem 286: 24426-
24433. 
28. Valdmanis PN, Simoes Lopes AA, Gros-Louis F, Stewart JD, Rouleau GA, et al. 
(2004) A novel neurodegenerative disease characterised by posterior column 
ataxia and pyramidal tract involvement maps to chromosome 8p12-8q12.1. J 
Med Genet 41: 634-639. 
29. Valdmanis PN, Brunet D, St-Onge J, Weston L, Rouleau GA, et al. (2006) A founder 
haplotype for autosomal dominant sensory ataxia in Eastern Canada. Neurology 
67: 2239-2242. 
 27 
30. Valdmanis PN, Dupre N, Lachance M, Stochmanski SJ, Belzil VV, et al. (2011) A 
mutation in the RNF170 gene causes autosomal dominant sensory ataxia. Brain 
134: 602-607. 
31. Saifi GM, Szigeti K, Wiszniewski W, Shy ME, Krajewski K, et al. (2005) SIMPLE 
mutations in Charcot-Marie-Tooth disease and the potential role of its protein 
product in protein degradation. Hum Mutat 25: 372-383. 
32. Tanabe K, Lennarz WJ, Suzuki T (2006) A cytoplasmic peptide: N-glycanase. 
Methods Enzymol 415: 46-55. 
33. Suzuki T, Park H, Lennarz WJ (2002) Cytoplasmic peptide:N-glycanase (PNGase) 
in eukaryotic cells: occurrence, primary structure, and potential functions. FASEB 
J 16: 635-641. 
34. Freeze HH, Aebi M (2005) Altered glycan structures: the molecular basis of 
congenital disorders of glycosylation. Curr Opin Struct Biol 15: 490-498. 
35. Habibi-Babadi N, Su A, de Carvalho CE, Colavita A (2010) The N-glycanase png-1 
acts to limit axon branching during organ formation in Caenorhabditis elegans. J 
Neurosci 30: 1766-1776. 
36. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB (2013) Genic intolerance 
to functional variation and the interpretation of personal genomes. PLoS Genet 9: 
e1003709. 
 
 
 
 
 28 
 FIGURE LEGENDS 
Figure 1 Relative frequency of clinical findings in NGLY1 deficiency.  
Figure 2 Pedigrees of NGLY1-deficienct patients. 
 
